Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation

Masahiro Shinoda, Hirotoshi Ebinuma, Osamu Itano, Yoshiyuki Yamagishi, Hideaki Obara, Minoru Kitago, Nobuhiro Nakamoto, Taizo Hibi, Hiroshi Yagi, Yuta Abe, Kentaro Matsubara, Hakusyo Cho, Yuko Wakayama, Nobuhito Taniki, Akihiro Yamaguchi, Ryusuke Amemiya, Rei Miyake, Takamasa Mizota, Takanori Kanai, Yuukou Kitagawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.

Original languageEnglish
Pages (from-to)1118-1128
Number of pages11
JournalHepatology Research
Volume46
Issue number11
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Ribavirin
Living Donors
Hepatitis C
Liver Transplantation
Interferons
Therapeutics
Simeprevir
Protease Inhibitors
Antiviral Agents
Genotype
Recurrence

Keywords

  • calcineurin inhibitor
  • direct-acting antiviral agent
  • living donor liver transplantation
  • recurrent hepatitis C
  • simeprevir
  • virological response

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. / Shinoda, Masahiro; Ebinuma, Hirotoshi; Itano, Osamu; Yamagishi, Yoshiyuki; Obara, Hideaki; Kitago, Minoru; Nakamoto, Nobuhiro; Hibi, Taizo; Yagi, Hiroshi; Abe, Yuta; Matsubara, Kentaro; Cho, Hakusyo; Wakayama, Yuko; Taniki, Nobuhito; Yamaguchi, Akihiro; Amemiya, Ryusuke; Miyake, Rei; Mizota, Takamasa; Kanai, Takanori; Kitagawa, Yuukou.

In: Hepatology Research, Vol. 46, No. 11, 01.10.2016, p. 1118-1128.

Research output: Contribution to journalArticle

@article{15df2b31df6b48daac2e51aebab9aa2f,
title = "Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation",
abstract = "Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80{\%}. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.",
keywords = "calcineurin inhibitor, direct-acting antiviral agent, living donor liver transplantation, recurrent hepatitis C, simeprevir, virological response",
author = "Masahiro Shinoda and Hirotoshi Ebinuma and Osamu Itano and Yoshiyuki Yamagishi and Hideaki Obara and Minoru Kitago and Nobuhiro Nakamoto and Taizo Hibi and Hiroshi Yagi and Yuta Abe and Kentaro Matsubara and Hakusyo Cho and Yuko Wakayama and Nobuhito Taniki and Akihiro Yamaguchi and Ryusuke Amemiya and Rei Miyake and Takamasa Mizota and Takanori Kanai and Yuukou Kitagawa",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/hepr.12666",
language = "English",
volume = "46",
pages = "1118--1128",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "11",

}

TY - JOUR

T1 - Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation

AU - Shinoda, Masahiro

AU - Ebinuma, Hirotoshi

AU - Itano, Osamu

AU - Yamagishi, Yoshiyuki

AU - Obara, Hideaki

AU - Kitago, Minoru

AU - Nakamoto, Nobuhiro

AU - Hibi, Taizo

AU - Yagi, Hiroshi

AU - Abe, Yuta

AU - Matsubara, Kentaro

AU - Cho, Hakusyo

AU - Wakayama, Yuko

AU - Taniki, Nobuhito

AU - Yamaguchi, Akihiro

AU - Amemiya, Ryusuke

AU - Miyake, Rei

AU - Mizota, Takamasa

AU - Kanai, Takanori

AU - Kitagawa, Yuukou

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.

AB - Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.

KW - calcineurin inhibitor

KW - direct-acting antiviral agent

KW - living donor liver transplantation

KW - recurrent hepatitis C

KW - simeprevir

KW - virological response

UR - http://www.scopus.com/inward/record.url?scp=84991112168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991112168&partnerID=8YFLogxK

U2 - 10.1111/hepr.12666

DO - 10.1111/hepr.12666

M3 - Article

C2 - 26854748

AN - SCOPUS:84991112168

VL - 46

SP - 1118

EP - 1128

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 11

ER -